Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14.

Read more at globenewswire.com